Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2023-01-04 00:00:00 ET · period of report 2022-12-30 · accession 0000899243-23-000755 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-04 | 2022-12-30 | AMLX | FRATES JAMES M | CFO | M - OptEx | $6.88 | +5,000 | 36.7K | +16% | +$34.4K |
| D | 2023-01-04 | 2022-12-30 | AMLX | FRATES JAMES M | CFO | M - OptEx | $0.00 | -5,000 | 447.0K | -1% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-30 | M | A | 5,000 | $6.88 | 36,667 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-12-30 | M | D | 5,000 | $0.00 | 447,000 | D | $6.88 · — to 2031-01-25 | 5,000 Common Stock | (F1) 113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter. |